The AI-Powered Future of Fertility

Intelligence Amplified: Combining Human Expertise with AI

  • The true power of the EM-Lux™ platform lies not just in its AI, but in its ability to amplify the embryologist's critical decision-making by providing objective, novel data. EM-Lux™ acts as an intelligent assistant, combining the best of human expertise with computational power.

  • Novel Biomarkers for Objective Assessment: The EMMI-AI Platform translates complex metabolic data derived from novel biomarkers into an objective viability score. This removes the inherent subjectivity and uncertainty associated with traditional embryo grading, which relies only on subjectively looking at the shape and size of embryos.

  • Enhancing Embryologist Visibility: The system provides embryologists with unprecedented, quantifiable insight into the embryo's cellular health and stress indicators—information that is completely invisible under a standard microscope.

Key Advantages …

  • Absolute Embryo Safety: EM-Lux™ is 100% non-invasive, preserving embryo integrity and eliminating biopsy risks.

  • Scientific Validation: Built on biomedical techniques, backed by over 25,000 publications across diverse medical fields.

  • Novel Biomarkers: Leverages novel metabolic biomarkers combined with conventional endpoints for objective viability assessment.

  • AI-Powered Confidence: EMMI-AI provides objective scoring and ranking for unprecedented diagnostic confidence.

  • Strong Academic Ties: Supported by partnerships with institutions like Stanford, University of California Irvine, and Cornell University.

  • The Em-Lux™ system is currently on the FDA approval track.

  • Given our broad clinical development and indication for improving IVF outcomes , anyone currently undergoing or preparing for an IVF journey is qualified for the EM-Lux™ diagnostics. This includes patients pursuing egg freezing, fresh embryo transfers, or frozen embryo transfers. Since the technology is non-invasive and provides data across 4 key touchpoints of the IVF cycle , patients can benefit from improved diagnostics at multiple stages, pending the final input and recommendation of their care provider or IVF clinic.

  • The primary advantage is the absolute preservation of embryo integrity. Our method is 100% non-invasive , eliminating the risks of damage, false positives, or sampling errors associated with invasive biopsy procedures like PGT-a. Furthermore, our system provides an objective viability assessment in real-time, which helps reduce the subjective nature of visual grading and speeds up the decision-making process for embryologists, ultimately aiming to increase the success rate on the first transfer.